L3VLUP
ProSign in

ALGN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALGNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALGN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterALGNVRTX
Q3 202022 holders, $4.0bn31 holders, $21.9bn
Q4 202021 holders, $6.4bn30 holders, $18.4bn
Q1 202130 holders, $6.5bn31 holders, $15.4bn
Q2 202129 holders, $6.5bn30 holders, $12.7bn
Q3 202126 holders, $8.1bn35 holders, $10.1bn
Q4 202121 holders, $8.4bn28 holders, $12.4bn
Q1 202220 holders, $6.1bn23 holders, $16.1bn
Q2 202217 holders, $3.4bn25 holders, $18.1bn
Q3 202219 holders, $2.7bn22 holders, $18.4bn
Q4 202216 holders, $2.2bn28 holders, $18.4bn
Q1 202319 holders, $3.8bn26 holders, $21.4bn
Q2 202320 holders, $4.1bn27 holders, $24.7bn
Q3 202318 holders, $2.9bn33 holders, $24.3bn
Q4 202320 holders, $2.4bn32 holders, $28.6bn
Q1 202419 holders, $2.7bn31 holders, $29.8bn
Q2 202418 holders, $1.6bn29 holders, $33.4bn
Q3 202415 holders, $2.1bn27 holders, $33.5bn
Q4 202417 holders, $1.5bn26 holders, $28.5bn
Q1 202517 holders, $1.3bn21 holders, $35.4bn
Q2 202517 holders, $1.5bn21 holders, $32.3bn
Q3 202511 holders, $751m22 holders, $25.9bn
Q4 202514 holders, $1.0bn26 holders, $31.8bn
Q1 202610 holders, $1.3bn25 holders, $31.8bn
Q2 202610 holders, $1.9bn26 holders, $34.6bn
ALGN

Align Technology Inc

Holders
19
Reported value
$2.7bn
Buyers
12
Sellers
8

Breadth +4 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALGN (7)

Arrowstreet Capital LP, Citadel Advisors LLC, Eisler Capital Management Ltd, Holocene Advisors LP, Point72 Asset Management LP, Polen Capital Management LLC, Woodline Partners LP

Only VRTX (19)

Acadian Asset Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →